Guilford to Present at UBS Global Life Sciences Conference

Guilford to Present at UBS Global Life Sciences Conference 


BALTIMORE, Sept. 22  /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc.
(NASDAQ:GLFD) announced today that it will present at the upcoming UBS Global
Life Sciences Conference on Tuesday, September 28, 2004 at 1:00 p.m. ET at the
Grand Hyatt Hotel in New York, NY.

Guilford's Chairman, President and CEO, Craig R. Smith, M.D., will provide an
update on the Company's business as well as new developments on products
currently in the pipeline.

To access the live audio webcast or the subsequent archived recording, log on
to http://www.guilfordpharm.com/.  The link for the webcast is located under
the Investor Relations section of the website under 'Conferences.'  Please
connect to the website several minutes prior to the start of the conference
call to ensure adequate time for any software download that may be necessary.

About Guilford

Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the
research, development and commercialization of proprietary drugs that target
the hospital and neurology markets.  Presently, Guilford markets two commercial
products, GLIADEL(R) Wafer (polifeprosan 20 with carmustine implant), for the
treatment of brain cancer, and AGGRASTAT(R) Injection (tirofiban
hydrochloride), a glycoprotein GP IIb/IIIa receptor antagonist, for the
treatment of acute coronary syndrome (ACS).  Guilford's product pipeline
includes AQUAVAN(R) Injection, a novel sedative/anesthetic and drugs for
treating peripheral nerve injury.  For full prescribing information, please
visit http://www.guilfordpharm.com/ under Products / Marketed Products.

CONTACT:  Stacey Jurchison, Director, Corporate Communications, Guilford
Pharmaceuticals, [phone]; . http://www.guilfordpharm.com/. 

DATASOURCE: Guilford Pharmaceuticals Inc.



CONTACT:  Stacey Jurchison, Director, Corporate Communications, Guilford

Pharmaceuticals, [phone], 



Web site:  http://www.guilfordpharm.com/ 



Company News On-Call:  http://www.prnewswire.com/comp/112882.html

Copyright